New Haven Pharmaceuticals Inc. (NHP), which plans to seek approval for a slow-release aspirin product next year, has received a $6.6 million Series A round from a mix of private and public investment groups.

The New Haven, Conn. company received $1.5 million from Connecticut Innovations (CI), a quasi-public authority aimed at helping innovative companies in the state. The remainder of the investment comes from EJ Funds, Kuzari Group, Advantage Capital Partners, Yale University, and individual investors, according to a statement from CI.